![]() ![]() Ideally, BenevolentAI's technology can amplify that information, opening up the possibility of finding more experimental drugs. And often, the scientists working on it have a very specialized understanding of a particular disease that influences how they approach the problem. This can be a lengthy process involving a lot of lab work and uncertainty over whether the drug will work when it is tested in animals. Traditionally, that company would seek to figure out the science behind a particular disease, working to find disease targets it could then design drugs to go after. To see how that works, picture a pharmaceutical company on the hunt for new drugs to develop. ![]() IBM's Watson AI has also been used in drug discovery. In March, TwoXar, a startup that uses its software to discover new experimental drugs for other companies, raised $10 million and Atomwise, which designs drugs that companies can then test out, raised $45 million in its series A round in March. The funding, which came from existing investors including Woodford Investment Management, values the six-year-old company at $2 billion, a unicorn status held by only a few biotech companies.Īpplying artificial intelligence to drug discovery - which can often be a long, expensive process - has started attracting more attention from investors. Applying artificial intelligence to drug discovery - which can often be a long, expensive process - has started attracting more attention from investors.īenevolentAI, a UK-based startup that uses artificial intelligence to discover new treatments just raised $115 million.The company uses artificial intelligence to help discover new drugs to treat conditions like Parkinson's disease and rare cancers.UK-based biotech unicorn BenevolentAI just raised $115 million at a $2 billion valuation.During the interim period, delivery will not be impacted and account teams and day-to-day dealings with each organization will remain unchanged. Icon will continue to operate fully independently until the transaction is complete. ![]() “While we look forward to bringing the strengths of the combined company to customers, we are committed to remaining fully focused on achieving project delivery goals for all customer studies, both now and in the future,” said Dr. In addition, through a combination of mobile & connected health platforms, a global site network, home health services and wearables expertise, the combined company will deliver differentiated decentralized and hybrid trial solutions. With increased functional, geographic and therapeutic scale, as well as expansive healthcare technology innovation, the combined company will be able to offer market-leading capabilities and services to meet customer needs. Their combined focus will be on applying transformational technology and innovation to execute clinical trials from Phase 1 to post-approval studies with the highest quality, expertise and speed. The consolidation brings together two growing organizations with similar cultures and values to create a leading healthcare intelligence and clinical CRO. in a cash and stock transaction valued at approximately $12 billion. Icon, a company creating a new paradigm for bringing clinical research to patients, has agreed to acquire PRA Health Sciences Inc.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |